Correction: This article was corrected for missing Funding/Support, Role of the Sponsors, and Additional Contributions statements on December 5, 2017.
Accepted for Publication: August 7, 2017.
Corresponding Author: Marcel O. Bonn-Miller, PhD, University of Pennsylvania Perelman School of Medicine, 3440 Market St, Ste 370, Philadelphia, PA 19104 (mbonn@pennmedicine.upenn.edu).
Author Contributions: Dr Bonn-Miller had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Bonn-Miller, Loflin, Thomas, Vandrey.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Bonn-Miller, Loflin, Marcu, Vandrey.
Critical revision of the manuscript for important intellectual content: Bonn-Miller, Loflin, Thomas, Hyke, Vandrey.
Statistical analysis: Loflin, Marcu.
Obtained funding: Bonn-Miller.
Administrative, technical, or material support: Bonn-Miller, Loflin, Thomas, Hyke, Vandrey.
Supervision: Bonn-Miller.
Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Drs Bonn-Miller, Thomas, and Vandrey reported serving as unpaid board members of the Institute for Research on Cannabinoids. Dr Bonn-Miller reported receiving personal fees from Zynerba Pharmaceuticals, the Lambert Center for the Study of Medicinal Cannabis and Hemp, the Realm of Caring Foundation, Tilray, CW Botanicals, Insys Therapeutics, International Cannabis and Cannabinoids Institute, the Medical Cannabis Institute, and Aphria. Dr Vandrey reported receiving personal fees from Zynerba Pharmaceuticals, CW Hemp, Battelle Memorial Institute, and Insys Pharmaceuticals. No other disclosures were reported.
Funding/Support: This project was funded by a grant from the Institute for Research on Cannabinoids (IROC), a 501(c)(3) nonprofit organization supported by individual donations.
Role of the Funder/Sponsor: Although Drs Bonn-Miller, Thomas, and Vandrey serve as unpaid board members of IROC, the institution played no part in the design or conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.
Additional Contributions: We thank the Realm of Caring Foundation for their facility and staff support for the execution of this project. They did not receive compensation for their contribution.
1.Whiting
PF, Wolff
RF, Deshpande
S,
et al. Cannabinoids for medical use: a systematic review and meta-analysis.
JAMA. 2015;313(24):2456-2473.
PubMedGoogle ScholarCrossref 2.Vandrey
R, Raber
JC, Raber
ME, Douglass
B, Miller
C, Bonn-Miller
MO. Cannabinoid dose and label accuracy in edible medical cannabis products.
JAMA. 2015;313(24):2491-2493.
PubMedGoogle ScholarCrossref 4.Babalonis
S, Haney
M, Malcolm
RJ,
et al. Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers.
Drug Alcohol Depend. 2017;172:9-13.
PubMedGoogle ScholarCrossref 5.Bergamaschi
MM, Queiroz
RH, Zuardi
AW, Crippa
JA. Safety and side effects of cannabidiol, a
Cannabis sativa constituent.
Curr Drug Saf. 2011;6(4):237-249.
PubMedGoogle ScholarCrossref 6.Crippa
JA, Crippa
AC, Hallak
JE, Martín-Santos
R, Zuardi
AW. Δ9-THC intoxication by cannabidiol-enriched cannabis extract in two children with refractory epilepsy.
Front Pharmacol. 2016;7:359.
PubMedGoogle ScholarCrossref